USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
VIDASYM, INC.
Address:
1673 CEDAR GLEN DR
LIBERTYVILLE, IL 60048-3924
Phone:
N/A
URL:
N/A
EIN:
145428323
DUNS:
830016551
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $715,056.00 3
STTR Phase I $458,863.00 2

Award List:

New drug Vida-5 for treating chronic kidney disease progression

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$219,123.00
Agency:
HHS
Principal Investigator:
Jinshyun R. Wu-wong – 847-863-9818
Abstract:
DESCRIPTION (provided by applicant): Twenty-six million people in America have chronic kidney disease (CKD). Anemia, cardiovascular diseases, secondary hyperparathyroidism, renal osteodystrophy and other complications are common in CKD. Current treatmentsincluding ACE inhibitors for CKD patients… More

Novel drug VS-105 for treatment of diabetic nephropathy

Award Year / Program / Phase:
2012 / STTR / Phase I
Award Amount:
$159,647.00
Agency:
HHS
Principal Investigator:
Jinshyun R. Wu-wong – 847-260-8432
Research Institution:
UNIVERSITY OF CHICAGO
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Twenty-six million people in America have chronic kidney disease (CKD). Diabetes is by far the leading cause of CKD (diabetic nephropathy), accounting for 44% of new cases of dialysis (in 2005). Current treatments including ACE inhibitors for CKD patients mainly… More

New drug VS-501 for treating hyperphosphatemia in chronic kidney disease

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$217,354.00
Agency:
HHS
Principal Investigator:
Jinshyun R. Wu-wong – 847-260-8432
Abstract:
DESCRIPTION (provided by applicant): Twenty-six million people in America have chronic kidney disease (CKD). Despite the various treatments available to CKD patients, the five-year survival rate is ~33%. Inadequately controlled serum phosphate levels in CKD can lead to various pathologies of… More

New drug VS-110 for treating inflammatory bowel diseases

Award Year / Program / Phase:
2013 / STTR / Phase I
Award Amount:
$299,216.00
Agency:
HHS
Principal Investigator:
Jinshyun R. Wu-wong – 847-260-8432
Research Institution:
UNIVERSITY OF CHICAGO
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Inflammatory bowel diseases (IBD) involve chronic inflammation of all or part of the digestive tract. Symptoms may include abdominal pain, severe diarrhea and malnutrition. IBD primarily includes ulcerative colitis (UC)and Crohn's disease (CD). In the West,… More

Clinical Development of a Stable Glucagon Formulation for Bi-hormonal Pump

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$278,579.00
Agency:
HHS
Principal Investigator:
Jinshyun R. Wu-wong – 847-260-8432
Abstract:
DESCRIPTION (provided by applicant): Osteoporosis is a major public health threat. National Osteoporosis Foundation estimated that the US national direct expenditures for osteoporotic hip fractures were at 17 billion in 2005 and it would increase to 25billion in 2025. Current treatments for… More